Myocardial viability in chronic ischemic heart disease: Comparison of delayed-enhancement magnetic resonance imaging with 99mTc-sestamibi and 18F-fluorodeoxyglucose single-photon emission computed tomography

Nuclear Medicine Communications

Volumn 30, Issue 8, 2009, Pages 610-616

  Liu, Qiong ^a   Zhao, Shihua ^a   Yan, Chaowu ^a   Lu, Minjie ^a   Jiang, Shiliang ^a   Zhang, Yan ^a   Li, Shiguo ^a   Liu, Yuqing ^a   Yang, Minfu ^a   He, Zuoxiang ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Coronary artery disease; Magnetic resonance imaging; Myocardial infarction

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ARTICLE; CELL VIABILITY; CHRONIC DISEASE; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG UPTAKE; ELECTROCARDIOGRAM; GLUCOSE METABOLISM; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; QUANTITATIVE ANALYSIS; SCAR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CHRONIC DISEASE; CICATRIX; FEMALE; FLUORODEOXYGLUCOSE F18; HEART; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MYOCARDIAL ISCHEMIA; TECHNETIUM TC 99M SESTAMIBI; TIME FACTORS; TISSUE SURVIVAL; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 68349098414     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32832b529e     Document Type: Article

References (35)

1. Schinkel AF, Poldermans D, Elhendy A, Bax JJ. Assessment of myocardial viability in patients with heart failure. J Nucl Med 2007; 48:1135-1146. (Pubitemid 47052654)
2. Kim RJ, Albert TS,Wible JH, Elliott MD, Allen JC, Lee JC, et al. Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction - an international, multicenter, double-blinded, randomized trial. Circulation 2008; 117:629-637.
3. Zhao S, Liu S, Janier M, Croisille P, Roux JP, Revel D. Dobutamine magnetic resonance imaging predicts contractile reserve of chronically dysfunctional myocardium: comparison with was fluorine-18 fluorodeoxyglucose positron emission tomography. Chin Med Sci J 2000; 15:29-34. (Pubitemid 30161101)
4. Yang MF, Dou KF, Jiang XJ, He ZX. Tc-99m sestamibi/F-18 FDG myocardial SPECT in Takayasu arteritis with coronary artery involvement. Clin Nucl Med 2007; 32:685-689.
5. 18F-FDG PET. J Nucl Med 2001; 42:1166-1173.
6. Di Carli MF, Asgarzadie F, Schelbert HR, Brunken RC, Laks H, Phelps ME, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995; 92:3436-3444.
7. Klein C, Nekolla SG, Bengel FM, Momose M, Sammer A, Haas F, et al. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography. Circulation 2002; 105:162-167. (Pubitemid 34084313)
8. 201Tl SPECT in dysfunctional myocardium: relation to early functional outcome after surgical revascularization in chronic ischemic heart disease. J Nucl Med 2007; 48:1096-1103.
9. 18F- fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2003; 41:1341-1348.
10. Bax JJ, Visser FC, Poldermans D, Elhendy A, Cornel JH, Boersma E, et al. Relationship between preoperative viability and postoperative improvement in LVEF and heart failure symptoms. J Nucl Med 2001; 42:79-86. (Pubitemid 32104782)
11. Marwick TH, Zuchowski C, Lauer MS, Secknus MA, Williams J, Lytle BW. Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. J Am Coll Cardiol 1999; 33:750-758.
12. Mule JD, Bax JJ, Zingone B, Martinelli F, Burelli C, Stefania A, et al. The beneficial effect of revascularization on jeopardized myocardium: reverse remodeling and improved long-term prognosis. Eur J Cardiothorac Surg 2002; 22:426-430. (Pubitemid 36153073)
13. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151-1158. (Pubitemid 34267418)
14. He ZX, Shi RF, Wu YJ, Tian YQ, Liu XJ, Wang SW, et al. Direct imaging of exercise-induced myocardial ischemia with fluorine-18-labeled deoxyglucose and Tc-99m-sestamibi in coronary artery disease. Circulation 2003; 108:1208-1213.
15. 18F-FDG SPECT in patients with ischemic left ventricular dysfunction. J Nucl Med 2006; 47:68-73.
16. Udelson JE. Steps forward in the assessment of myocardial viability in left ventricular dysfunction. Circulation 1998; 97:833-838. (Pubitemid 28113919)
17. 18F-FDG PET. Eur J Med Mol Imaging 2006; 33:716-723.
18. 99mTc-sestamibi to assess myocardial viability and function in a single study. Eur J Nucl Med Mol Imaging 2005; 32:195-202.
19. Chen EQ, MacIntyre WJ, Go RT, Brunken RC, Saha GB, Wong CY, et al. Myocardial viability studies using fluorine-18-FDG SPECT: a comparison with fluorine-18-FDG PET. J Nucl Med 1997; 38:582-586. (Pubitemid 27163653)
20. Kim RJ, Manning WJ. Viability assessment by delayed enhancement cardiovascular magnetic resonance: will low-dose dobutamine dull the shine? Circulation 2004; 109:2476-2479.
21. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999; 100:1992-2002. (Pubitemid 29529292)
22. Fieno DS, Kim RJ, Chen EL, Lomasney JW, Klocke FJ, Judd RM. Contrast-enhanced magnetic resonance imaging of myocardium at risk: distinction between reversible and irreversible injury throughout infarct healing. J Am Coll Cardiol 2000; 36:1985-1991.
23. Higuchi T, Nekolla SG, Jankaukas A,Weber AW, Huisman MC, Reder S, et al. Characterization of normal and infarcted rat myocardium using a combination of small-animal PET and clinical MRI. J Nucl Med 2007; 48:288-294. (Pubitemid 47555356)
24. Rehwald WG, Fieno DS, Chen EL, Kim RJ, Judd RM. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 2002; 105:224-229.
25. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343:1445-1453. (Pubitemid 30832880)
26. Schvartzman PR, Srichai MB, Grimm RA, Obuchowski NA, Hammer DF, McCarthy PM, et al. Nonstress delayed-enhancement magnetic resonance imaging of the myocardium predicts improvement of function after revascularization for chronic ischemic heart disease with left ventricular dysfunction. Am Heart J 2003; 146:535-541. (Pubitemid 37083091)
27. Kuhl HP, Lipke CS, Krombach GA, Katoh M, Battenberg TF, Nowak B, et al. Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography-single photon emission computed tomography imaging protocol. Eur Heart J 2006; 27:846-853.
28. Gibbons R, Valeti U, Araoz P, Jaffe AS. The quantification of infarct size. J Am Coll Cardiol 2004; 44:1533-1542.
29. Wu E, Judd RM, Vargas JD, Klocke FJ, Bonow RO, Kim RJ. Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction. Lancet 2001; 357:21-28. (Pubitemid 32056497)
30. Knuesel PR, Nanz D,Wyss C, Buechi M, Kaufmann PA, von Schulthess GK, et al. Characterization of dysfunctional myocardium by positron emission tomography and magnetic resonance: relation to functional outcome after revascularization. Circulation 2003; 108:1095-1100. (Pubitemid 37071520)
31. Wagner A, Mahrholdt H, Holly T, Elliott M, Regenfus M, Parker M, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: an imaging study. Lancet 2003; 361:374-379. (Pubitemid 36164969)
32. Jachson E, Bellenger N, Seddon M, Harden S, Peebles C. Ischaemic and non-ischaemic cardiomyopathies - cardiac MRI appearances with delayed enhancement. Clin Radiol 2007; 62:395-403. (Pubitemid 46477782)
33. De Boeck B, Verburg F, Hobbelink M, Velthuis B, Melman PG, Cramer MJ. Reversible 18-FDG-uptake defects on myocardial PET: Is this myocardial resurrection? Int J Cardiol 2008; 127:e175-e178.
34. Kim RJ, Shah DJ. Fundamental concepts in myocardial viability assessment revisited: when knowing how much is alive is not enough. Heart 2004; 90:137-140.
35. Gutberlet M, Frohlich M, Mehl S, Amthauer H, Hausmann H, Meyer R, et al. Myocardial viability assessment in patients with highly impaired left ventricular function: comparison of delayed enhancement, dobutamine stress MRI, end-diastolic wall thickness, and TI201-SPECT with functional recovery after revascularization. Eur Radiol 2005; 15:872-880. (Pubitemid 41166718)